Welcome to our dedicated page for Centene news (Ticker: CNC), a resource for investors and traders seeking the latest updates and insights on Centene stock.
Centene Corporation reports news on its government-sponsored managed care business, including Medicaid, Medicare, individual exchange coverage and Medicare Part D plans. Company updates commonly cover quarterly results, EPS guidance, membership by line of business and health-plan subsidiary activity across state markets.
Centene news also includes initiatives from the Centene Foundation and operating companies such as Health Net, Superior HealthPlan, Home State Health, Sunshine Health, Buckeye Health Plan, Carolina Complete Health and WellCare of Kentucky. Recurring themes include affordable housing, medically tailored meals, provider accessibility, workforce development, community health, social services and programs that address drivers of health for managed care members.
Health Net is providing urgent assistance to its members in Humboldt County following a state of emergency declared by Governor Gavin Newsom due to an earthquake. This initiative ensures members have access to essential prescription medications and healthcare services. Members can obtain emergency supplies at their original pharmacies or call Health Net for assistance. Additionally, Health Net offers telehealth services at no cost, mental health support, and guidance for healthcare providers during this crisis.
Centene Corporation (NYSE: CNC) will present at the JP Morgan 41st Annual Healthcare Conference from January 9-12, 2023, in California. The presentation is scheduled for January 9 at 7:30 a.m. Pacific Time. Investors can access a live audio webcast at this link. A replay will be available on Centene's website under the Investors section. Centene is committed to providing high-quality healthcare services, focusing on underserved populations.
Centene Corporation (CNC) has announced its financial guidance for 2023, projecting adjusted diluted EPS between $6.25 and $6.40, with revenue expectations ranging from $137.4 billion to $139.4 billion. The company aims for a 12% - 15% compound annual growth rate (CAGR) for adjusted diluted EPS in the long term. The Board has approved a $2 billion increase to its stock repurchase program. For 2022, Centene reaffirms its guidance for total revenues between $142.7 billion and $144.7 billion, with adjusted EPS of $5.65 to $5.75.
Centene Corporation (NYSE: CNC) announced significant leadership changes to propel future growth, with Ken Fasola appointed President, succeeding his role as EVP of Health Care Enterprises. Jim Murray becomes COO, enhancing operational effectiveness. Dave Thomas steps into CEO of Markets and Medicaid, while Brent Layton transitions to Senior Advisor as he approaches retirement. Alice H. Chen and Brian LeClaire join as Chief Health Officer and Chief Information Officer, respectively, strengthening the executive team. These changes aim to align talent with Centene's mission of delivering quality healthcare and increasing shareholder value.
Centene Corporation (NYSE: CNC) will host an investor day on December 16, 2022, starting at 8:30 a.m. EST. The event, featuring CEO Sarah London and the management team, includes a live question-and-answer session and will be webcast from the New York Stock Exchange. In-person attendance is by invitation only, but the meeting can be accessed via live webcast on Centene's website. Centene focuses on providing integrated healthcare services to under-insured and uninsured individuals.
Centene Corporation (CNC) has completed the divestiture of Magellan Rx to Prime Therapeutics, aligning with its value creation plan. This move allows Centene to concentrate on its core operations and strategic priorities. Centene had initially acquired Magellan Rx in January 2022 as part of the broader acquisition of Magellan Health. The company continues to emphasize its commitment to delivering high-quality healthcare services, particularly to under-insured and uninsured individuals, while focusing on long-term growth and value creation for its shareholders.
Centene Corporation (NYSE: CNC) announced an investment of $7.9 million in a new community center in Uvalde, Texas. This initiative, in partnership with Community Health Development, Inc., aims to enhance access to primary care, behavioral health, and youth resources. A groundbreaking ceremony took place on Dec. 2, 2022. The center is designed to support the community's long-term recovery following the Robb Elementary School tragedy and is expected to be completed by late 2024. Centene emphasizes the importance of local relationships in delivering effective healthcare services.
Health Net is responding to the declared state of emergency in Alpine, El Dorado, Inyo, Los Angeles, and Placer counties due to wildfires and flash flooding. The company is providing special assistance to ensure members can access essential prescription medications and healthcare services. During this emergency, members can obtain emergency prescription supplies from their pharmacy or contact Health Net for assistance. Health Net also offers telehealth services and mental health support through MHN. They are committed to ensuring continued healthcare access during this crisis.
Centene Corporation (NYSE: CNC) has signed an agreement to sell Magellan Specialty Health to Evolent Health, expecting over $750 million in total proceeds. The deal includes $600 million at closing, with $400 million in cash and the remaining in Evolent stock. An additional $150 million may be earned based on performance metrics in 2024. This transaction aims to create a strategic partnership, enhancing Centene’s portfolio of specialty solutions. The sale is anticipated to close in the first half of 2023, pending regulatory approvals.
Evolent Health announced its agreement to acquire NIA, a specialty benefit management organization owned by Centene, for $650 million. The acquisition, set to close in mid-2023, is expected to add $85 million in adjusted EBITDA by 2024 and enhance Evolent’s value-based specialty care leadership. The deal diversifies Evolent's revenue base and increases cross-selling opportunities from $16 billion to $50 billion. The NIA acquisition will maintain Evolent's strong balance sheet and is projected to immediately improve cash flow and adjusted EBITDA margins.